Bayer CropScience Performance degli utili passati
Criteri Il passato verificati 6/6
Bayer CropScience ha registrato una crescita degli utili a un tasso medio annuo di 3.7%, mentre il settore Chemicals ha registrato utili in crescita a un tasso medio annuo di 6.4%. I ricavi sono stati in crescita a un tasso medio annuo di 5.5%. Il ritorno sul capitale proprio di Bayer CropScience è 21.5% e ha margini netti di 11.9%.
Informazioni chiave
3.72%
Tasso di crescita degli utili
3.72%
Tasso di crescita dell'EPS
| Chemicals Crescita del settore | 17.68% |
| Tasso di crescita dei ricavi | 5.45% |
| Rendimento del capitale proprio | 21.46% |
| Margine netto | 11.93% |
| Ultimo aggiornamento sugli utili | 31 Dec 2025 |
Aggiornamenti sulle prestazioni recenti
Recent updates
506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook
Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook
The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook
Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook
Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook
Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook
Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year
Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025
Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025
Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.Seeds, Traits And Biofuels Will Unlock New Value Pools
Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.Ripartizione dei ricavi e delle spese
Come Bayer CropScience guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Dec 25 | 56,206 | 6,704 | 7,462 | 0 |
| 30 Sep 25 | 55,718 | 6,089 | 7,540 | 0 |
| 30 Jun 25 | 57,566 | 5,925 | 7,574 | 0 |
| 31 Mar 25 | 54,734 | 5,680 | 7,527 | 0 |
| 31 Dec 24 | 52,172 | 5,207 | 7,208 | 0 |
| 30 Sep 24 | 51,152 | 5,796 | 7,116 | 0 |
| 30 Jun 24 | 49,948 | 6,662 | 6,965 | 0 |
| 31 Mar 24 | 51,062 | 7,405 | 6,902 | 0 |
| 31 Dec 23 | 52,942 | 8,030 | 7,684 | 0 |
| 30 Sep 23 | 53,772 | 8,444 | 8,020 | 0 |
| 30 Jun 23 | 52,119 | 7,841 | 8,299 | 0 |
| 31 Mar 23 | 51,397 | 7,582 | 8,616 | 0 |
| 31 Dec 22 | 51,205 | 7,524 | 8,381 | 0 |
| 30 Sep 22 | 50,727 | 7,027 | 8,313 | 0 |
| 30 Jun 22 | 49,859 | 6,942 | 8,027 | 0 |
| 31 Mar 22 | 47,344 | 6,453 | 7,836 | 0 |
| 31 Dec 21 | 45,048 | 5,545 | 6,549 | 0 |
| 30 Sep 21 | 44,329 | 4,246 | 6,090 | 0 |
| 30 Jun 21 | 44,494 | 4,951 | 5,858 | 0 |
| 31 Mar 21 | 42,613 | 4,931 | 5,726 | 0 |
| 31 Dec 20 | 39,913 | 4,627 | 5,706 | 0 |
| 30 Sep 20 | 39,271 | 6,457 | 5,559 | 0 |
| 30 Jun 20 | 38,918 | 5,909 | 5,703 | 0 |
| 31 Mar 20 | 36,094 | 4,745 | 5,729 | 0 |
| 31 Dec 19 | 29,294 | 2,864 | 5,437 | 0 |
| 30 Sep 19 | 28,505 | 2,116 | 5,580 | 0 |
| 30 Jun 19 | 25,256 | 1,497 | 5,427 | 0 |
| 31 Mar 19 | 31,754 | 3,371 | 6,010 | 0 |
| 31 Dec 18 | 28,639 | 3,045 | 4,621 | 0 |
| 30 Sep 18 | 27,226 | 2,877 | 4,476 | 0 |
| 30 Jun 18 | 28,505 | 3,356 | 4,392 | 0 |
| 31 Mar 18 | 27,167 | 3,001 | 4,327 | 0 |
| 31 Dec 17 | 26,375 | 2,769 | 4,280 | 0 |
| 30 Sep 17 | 28,203 | 3,030 | 4,242 | 0 |
| 30 Jun 17 | 26,796 | 2,715 | 2,507 | 0 |
| 31 Mar 17 | 28,153 | 2,910 | 4,129 | 0 |
| 31 Dec 16 | 40,105 | 3,323 | 4,219 | 0 |
| 30 Sep 16 | 32,030 | 3,342 | 3,519 | 0 |
| 30 Jun 16 | 38,027 | 3,215 | 4,116 | 0 |
| 31 Mar 16 | 27,838 | 3,151 | 4,073 | 0 |
| 31 Dec 15 | 37,919 | 3,278 | 6,458 | 0 |
| 30 Sep 15 | 38,569 | 3,554 | 6,469 | 0 |
| 30 Jun 15 | 39,222 | 3,814 | 6,433 | 0 |
Guadagni di qualità: 506285 ha guadagni di alta qualità.
Margine di profitto in crescita: Gli attuali margini di profitto netti di 506285 (11.9%) 506285 sono più alti rispetto allo scorso anno (10%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di 506285 sono cresciuti del 3.7% all'anno negli ultimi 5 anni.
Accelerare la crescita: La crescita degli utili di 506285 nell'ultimo anno ( 28.7% ) supera la media quinquennale ( 3.7% all'anno).
Guadagni vs Settore: La crescita degli utili 506285 nell'ultimo anno ( 28.7% ) ha superato la percentuale del settore Chemicals 10.3%.
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 21.5% ) di 506285 è considerato alto.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/26 09:28 |
| Prezzo dell'azione a fine giornata | 2026/05/26 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Bayer CropScience Limited è coperta da 26 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Himanshu Binani | Anand Rathi Shares and Stock Brokers Limited |